Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is usually constitutively activated in a variety of malignancies. Therefore, STAT3 may be a promising target for treatment of tumor cells. To explore the possibility of a double-stranded decoy oligodeoxynucleotide (ODN) targeted blocking STAT3 over-activated tumor cells, we, here, evaluate the efficacy of STAT3 decoy ODN on human lung cancer cells in vitro and in vivo. METHODS: A STAT3 decoy ODN was transfected into A549 lung cancer cell line in vitro by using lipofectamine. The flow cytometry and fluorescent microscopy were used to detect the transfection efficiency and the sub-cellular localization of STAT3 decoy ODN in A549 cells. Cell proliferation was determined by counting cell numbers and [3H]-thymidine uptake. Cell apoptosis was examined with Annexin V and propidum iodide by flow cytometry. The expression levels of STAT3 target genes were identified by RT-PCR and immunoblot. For in vivo experiment, A549 lung carcinoma-nude mice xenograft was used as a model to examine the effect of the STAT3 decoy by intratumoral injection. At the end of treatment, TUNEL and immunohistochemistry were used to examine the apoptosis and the expression levels of bcl-xl and cyclin D1 in tumor tissues. RESULTS: STAT3 decoy ODN was effectively transfected into A549 lung cancer cells and mainly located in nucleus. STAT3-decoy ODN significantly induced apoptosis and reduced [3H]-thymidine incorporation of A549 cells as well as down-regulated STAT3-target genes in vitro. STAT3 decoy ODN also dramatically inhibited the lung tumor growth in xenografted nude mice and decreased gene expression of bcl-xl and cyclin D1. CONCLUSION: STAT3 decoy ODN significantly suppressed lung cancer cells in vitro and in vivo, indicating that STAT3 decoy ODN may be a potential therapeutic approach for treatment of lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 2×
“The constantly activated STAT3 contributes to oncogenesis by up-regulation of genes encoding bcl-xl, bcl-2, c-myc, cyclin D1, survivin, mcl-1 [7,8,16,19], and VEGF, IL-10, TGF-β et al [20-22], which can protect apoptosis, enhance cell proliferation, promote angiogenesis and evade immune surveillance [1].”
BackgroundZhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · cited 1×
“Upon activation, STAT3 dimers translocate into the nucleus, where they bind to STAT3 specific DNA response elements and activate their transcription [4,5].”
BackgroundCatlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
The Stat family in cytokine signaling
Ihle, J. N. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00199-x · Cited by 713 · cited 1×
“Upon activation, STAT3 dimers translocate into the nucleus, where they bind to STAT3 specific DNA response elements and activate their transcription [4,5].”
BackgroundEpling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 2×
“The constantly activated STAT3 contributes to oncogenesis by up-regulation of genes encoding bcl-xl, bcl-2, c-myc, cyclin D1, survivin, mcl-1 [7,8,16,19], and VEGF, IL-10, TGF-β et al [20-22], which can protect apoptosis, enhance cell proliferation, promote angiogenesis and evade immune surveillance [1].”
BackgroundGritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563 · cited 2×
“Though there are multiple oncogenic signaling pathways in each individual tumor, blockade of STAT3 signaling is often sufficient to induce growth arrest and apoptosis in many different tumors [8-12,16].”
BackgroundActivation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393 · cited 1×
“Dysregulation and constitutive activation of STAT3 have been found in numerous primary cancers such as lymphomas, leukemias, multiple myelomas, prostate, breast, lung, head and neck, melanoma, pancreas, ovary and gastric cancer cells [6-16].”
BackgroundSOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
He, B., You, L., Uematsu, K., Zang, K., Xu, Z., Lee, A. Y., Costello, J. F., McCormick, F., & Jablons, D. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232790100 · Cited by 380
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340 · cited 2×
“This strategy has been successfully used for inhibition of STAT3 in head and neck cancer and also for inactivation of STAT6 in shifting IL-4driven Th2 cell activity [27,28].”
BackgroundMethodInterleukin-6 Induces Both Cell Growth and VEGF Production in Malignant Mesotheliomas
Adachi, Y., Aoki, C., Yoshio‐Hoshino, N., Takayama, K., Curiel, D. T., & Nishimoto, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.22006 · Cited by 115
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Targeting STAT3 in cancer: how successful are we?
Yue, P., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 413
STAT3 SIGNALING: Anticancer Strategies and Challenges
Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 406
Role of STAT3 in Cancer Metastasis and Translational Advances
Kamran, M. Z., Patil, P., & Gude, R. P. (2013) · BioMed Research International · doi:10.1155/2013/421821 · Cited by 393
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
Self-citation
Metadata
- Authors
- Zhang, X., Zhang, J., Wang, L., Wei, H., & Tian, Z.
- Venue
- BMC Cancer
- Published
- 2007-08-04
- Volume
- 7
- Issue
- 1
- Pages
- 149-149
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2027441131
- Cited by
- 113
- References
- 13
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.